A Randomized, Open-label Phase 3 Study of Amivantamab + FOLFIRI Versus Cetuximab/Bevacizumab + FOLFIRI in Participants With KRAS/NRAS and BRAF Wild-type Recurrent, Unresectable or Metastatic Colorectal Cancer Who Have Received Prior Chemotherapy
A Randomized, Open-label Phase 3 Study of Amivantamab + FOLFIRI Versus Cetuximab/Bevacizumab + FOLFIRI in Participants With KRAS/NRAS and BRAF Wild-type Recurrent, Unresectable or Metastatic Colorectal Cancer Who Have Received Prior Chemotherapy
The purpose of this study is to compare how long the participants are disease-free (progression-free survival) and and the length of time until a participant dies (overall survival), when treated with amivantamab and chemotherapy with 5-fluorouracil, leucovorin calcium (folinic acid) or levoleucovorin, and irinotecan hydrochloride (FOLFIRI) versus either cetuximab or bevacizumab and FOLFIRI given to participants with Kirsten rat sarcoma viral oncogene/ neuroblastoma RAS viral oncogene homolog (KRAS/ NRAS) and v-raf murine sarcoma viral oncogene homolog B (BRAF) wild-type recurrent, unresectable or metastatic colorectal cancer who have previously received chemotherapy.
Inclusion Criteria:
Exclusion Criteria:
Participate-In-This-Study1@its.jnj.com844-434-4210
Aurora, Colorado 80045, United States
Frederick, Maryland 21702, United States
Grand Rapids, Michigan 49503, United States
New York, New York 10016, United States
Pittsburgh, Pennsylvania 15232 1301, United States
South Woodville, 5011, Australia
Haine Saint Paul La Louviere, 7100, Belgium
Liège, 4000, Belgium
São José do Rio Preto, 15090 000, Brazil
São Paulo, 01246 000, Brazil
São Paulo, 05651 900, Brazil
Vitória, 29043 260, Brazil
Beer Yaakov, 70300, Israel
Bialystok, 15 027, Poland
Brzozów, 36 200, Poland
Gliwice, 44 100, Poland
Warsaw, 02 034, Poland
Ankara, 06200, Turkey (Türkiye)
Istanbul, 34899, Turkey (Türkiye)